Functional selectivity of EGF family peptide growth factors: Implications for cancer

Kristy J. Wilson, Jennifer L. Gilmore, John Foley, Mark A. Lemmon, David J. Riese

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Breast, prostate, pancreatic, colorectal, lung, and head and neck cancers exploit deregulated signaling by ErbB family receptors and their ligands, EGF family peptide growth factors. EGF family members that bind the same receptor are able to stimulate divergent biological responses both in cell culture and in vivo. This is analogous to the functional selectivity exhibited by ligands for G-protein coupled receptors. Here we review this literature and propose that this functional selectivity of EGF family members is due to distinctions in the conformation of the liganded receptor and subsequent differences in the sites of receptor tyrosine phosphorylation and receptor coupling to signaling effectors. We also discuss the roles of divergent ligand activity in establishing and maintaining malignant phenotypes. Finally, we discuss the potential of mutant EGF family ligands as cancer chemotherapeutics targeted to ErbB receptors.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPharmacology and Therapeutics
Volume122
Issue number1
DOIs
StatePublished - Apr 2009

Fingerprint

Epidermal Growth Factor
Intercellular Signaling Peptides and Proteins
Ligands
Peptides
Neoplasms
Head and Neck Neoplasms
G-Protein-Coupled Receptors
Prostate
Lung Neoplasms
Breast
Cell Culture Techniques
Phosphorylation
Phenotype
ErbB Receptors

Keywords

  • Amphiregulin
  • EGF
  • Epidermal growth factor receptor
  • ErbB receptors
  • ErbB4
  • Neuregulins
  • Signal transduction
  • Transforming growth factor alpha

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Functional selectivity of EGF family peptide growth factors : Implications for cancer. / Wilson, Kristy J.; Gilmore, Jennifer L.; Foley, John; Lemmon, Mark A.; Riese, David J.

In: Pharmacology and Therapeutics, Vol. 122, No. 1, 04.2009, p. 1-8.

Research output: Contribution to journalArticle

Wilson, Kristy J. ; Gilmore, Jennifer L. ; Foley, John ; Lemmon, Mark A. ; Riese, David J. / Functional selectivity of EGF family peptide growth factors : Implications for cancer. In: Pharmacology and Therapeutics. 2009 ; Vol. 122, No. 1. pp. 1-8.
@article{890a9c5bea914ebebe3c73ab0eb3817d,
title = "Functional selectivity of EGF family peptide growth factors: Implications for cancer",
abstract = "Breast, prostate, pancreatic, colorectal, lung, and head and neck cancers exploit deregulated signaling by ErbB family receptors and their ligands, EGF family peptide growth factors. EGF family members that bind the same receptor are able to stimulate divergent biological responses both in cell culture and in vivo. This is analogous to the functional selectivity exhibited by ligands for G-protein coupled receptors. Here we review this literature and propose that this functional selectivity of EGF family members is due to distinctions in the conformation of the liganded receptor and subsequent differences in the sites of receptor tyrosine phosphorylation and receptor coupling to signaling effectors. We also discuss the roles of divergent ligand activity in establishing and maintaining malignant phenotypes. Finally, we discuss the potential of mutant EGF family ligands as cancer chemotherapeutics targeted to ErbB receptors.",
keywords = "Amphiregulin, EGF, Epidermal growth factor receptor, ErbB receptors, ErbB4, Neuregulins, Signal transduction, Transforming growth factor alpha",
author = "Wilson, {Kristy J.} and Gilmore, {Jennifer L.} and John Foley and Lemmon, {Mark A.} and Riese, {David J.}",
year = "2009",
month = "4",
doi = "10.1016/j.pharmthera.2008.11.008",
language = "English",
volume = "122",
pages = "1--8",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Functional selectivity of EGF family peptide growth factors

T2 - Implications for cancer

AU - Wilson, Kristy J.

AU - Gilmore, Jennifer L.

AU - Foley, John

AU - Lemmon, Mark A.

AU - Riese, David J.

PY - 2009/4

Y1 - 2009/4

N2 - Breast, prostate, pancreatic, colorectal, lung, and head and neck cancers exploit deregulated signaling by ErbB family receptors and their ligands, EGF family peptide growth factors. EGF family members that bind the same receptor are able to stimulate divergent biological responses both in cell culture and in vivo. This is analogous to the functional selectivity exhibited by ligands for G-protein coupled receptors. Here we review this literature and propose that this functional selectivity of EGF family members is due to distinctions in the conformation of the liganded receptor and subsequent differences in the sites of receptor tyrosine phosphorylation and receptor coupling to signaling effectors. We also discuss the roles of divergent ligand activity in establishing and maintaining malignant phenotypes. Finally, we discuss the potential of mutant EGF family ligands as cancer chemotherapeutics targeted to ErbB receptors.

AB - Breast, prostate, pancreatic, colorectal, lung, and head and neck cancers exploit deregulated signaling by ErbB family receptors and their ligands, EGF family peptide growth factors. EGF family members that bind the same receptor are able to stimulate divergent biological responses both in cell culture and in vivo. This is analogous to the functional selectivity exhibited by ligands for G-protein coupled receptors. Here we review this literature and propose that this functional selectivity of EGF family members is due to distinctions in the conformation of the liganded receptor and subsequent differences in the sites of receptor tyrosine phosphorylation and receptor coupling to signaling effectors. We also discuss the roles of divergent ligand activity in establishing and maintaining malignant phenotypes. Finally, we discuss the potential of mutant EGF family ligands as cancer chemotherapeutics targeted to ErbB receptors.

KW - Amphiregulin

KW - EGF

KW - Epidermal growth factor receptor

KW - ErbB receptors

KW - ErbB4

KW - Neuregulins

KW - Signal transduction

KW - Transforming growth factor alpha

UR - http://www.scopus.com/inward/record.url?scp=63049100044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049100044&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2008.11.008

DO - 10.1016/j.pharmthera.2008.11.008

M3 - Article

C2 - 19135477

AN - SCOPUS:63049100044

VL - 122

SP - 1

EP - 8

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -